

PTO/SB/98 (04-07)

Approved for use through 09/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Novartis Forschungsförderung Zweigniederlassung Friedrich Miescher Institute for BiomedicalApplication No./Patent No.: 10/533,503 Filed/Issue Date: October 26, 2005Entitled: TEU/ETV6 MEDIATED INHIBITION OF CELLNovartis Forschungsförderung Zweigniederlassung Friedrich Miescher Institutefor Biomedical Research, a Corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest
(The extent (by percentage) of its ownership interest is _____ %)

In the patent application/patent identified above by virtue of either:

- A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.☐ As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

_____	14.05.2008
Signature	Date
Dr. Nicolas Favre	+41 61 697 8382
Printed or Typed Name	Telephone Number
Head Patents & Licensing	
Title	

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FCCS OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ASSIGNMENT

I / We **Ali BADACHE**, 27, rue du Stade, 68170 Rixheim, France, citizen of France and
Nancy HYNES, Lerchenstrasse 2, 4059 Basel, Switzerland, citizen of the
United States of America and
Nicole SCHICK, 2801 Camino Del Mar Apt. # 8, Del Mar, CA 92014, USA, citizen
of Germany,

for good and valuable consideration, the receipt and adequacy of which is hereby
acknowledged, do hereby sell and assign to **Novartis Forschungsstiftung,
Zweigniederlassung Friedrich Miescher Institute for Biomedical Research, an
organization registered according to the laws of Switzerland, of Maulbeerstrasse 66,
4058 Basel, Switzerland**, its successors, assigns and legal representatives all my/our right,
title and interest, in and for the United States of America, in and to the invention entitled:

TEL/Etv6-mediated inhibition of cell proliferation

invented by me/us and described in the international application

No. **PCT/EP 2003/012295** filed **November 4, 2003**

and all United States Letters Patent which may be granted therefor, and all divisions,
reissues, continuations and extensions thereof, the said interest being the entire ownership
of the said Letters Patent when granted, to be held and enjoyed by the said **Novartis
Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute for Biomedical
Research**, its successors, assigns or other legal representatives, to the full end of the term
for which said Letters Patent may be granted, as fully and entirely as the same would have
been held and enjoyed by me/us if this assignment and sale had not been made;

And I/we hereby authorize and request the Commissioner of Patents and Trademarks to
issue said Letters Patent to the said **Novartis Forschungsstiftung, Zweigniederlassung
Friedrich Miescher Institute for Biomedical Research**.

Signed on

A. BADACHE

Ali BADACHE

April 14, 2005

Nancy Hynes

Nancy HYNES

April 14, 2005

Nicole Schick

Nicole SCHICK

April 18, 2005